ALINA STANCA: Open Payments
NPI 1720381163 · EL MIRAGE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$596 in 27 payments from 12 companies in 2025. Trend: 2023 $269 · 2024 $0 · 2025 $596
Food & beverage: $539Education: $57
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 13 | $183 |
| Lilly USA, LLC | 1 | $123 |
| SANOFI-AVENTIS U.S. LLC | 1 | $57 |
| BioCryst US Sales Co., LLC | 2 | $44 |
| Novartis Pharmaceuticals Corporation | 2 | $37 |
| GENZYME CORPORATION | 2 | $34 |
| Genentech USA, Inc. | 1 | $29 |
| Grifols USA, LLC | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
Products named: NUCALA, EBGLYSS, DUPIXENT, ORLADEYO, Xolair, Xembify, CUVITRU, General - Pain Management.
Industry payments across AZ — which companies pay providers there.
